(PDF) Does Afatinib Plus Bevacizumab Combination Therapy

Does Afatinib Plus Bevacizumab Combination Therapy Induce Positive Conversion of T790M in Previously-Negative Patients?

Oncotarget - United States

doi 10.18632/oncotarget.26192

Full Text

Open PDF

Abstract

Available in full text

Date

September 24, 2018

Authors

Publisher

Impact Journals, LLC

Related search

Osimertinib for Secondary T790m-Mutation–Positive Squamous Cell Carcinoma Transformation After Afatinib Failure

Journal of Thoracic Oncology

English

Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

Cancer immunology research

Cancer Research

Immunology

2014

English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology

English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology

English

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Cancer Research and Treatment

Cancer Research

Oncology

2019

English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Clinical and Economic Study of Daratumumab in Combination Therapy for Previously Treated Patients With Multiple Myeloma

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)

2019

English

Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)

English

Amanote Research

Does Afatinib Plus Bevacizumab Combination Therapy Induce Positive Conversion of T790M in Previously-Negative Patients?

Oncotarget - United States

doi 10.18632/oncotarget.26192

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Osimertinib for Secondary T790m-Mutation–Positive Squamous Cell Carcinoma Transformation After Afatinib Failure

Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Clinical and Economic Study of Daratumumab in Combination Therapy for Previously Treated Patients With Multiple Myeloma

Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)